Verrica Pharmaceuticals (NASDAQ:VRCA) Issues Quarterly Earnings Results

Posted by George Bondi on Aug 7th, 2026

Verrica Pharmaceuticals (NASDAQ:VRCA – Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.07), FiscalAI reports. Verrica Pharmaceuticals had a negative return on equity of 1,077.78% and a negative net margin of 47.97%.The business had revenue of $5.86 million during the quarter, compared to analyst estimates of $5.73 million.

Here are the key takeaways from Verrica Pharmaceuticals’ conference call:

YCANTH unit growth accelerated, with dispensed applicator units rising 28% sequentially to 19,626 and U.S. net product revenue increasing 18.7% to $5.1 million. Management attributed the momentum to improved prescriber targeting, field-force execution, and patient access initiatives.
Verrica and Torii began dosing patients in the second pivotal common-warts trial, COVE3, while COVE2 enrollment remains on schedule for top-line data in mid-2027. The company is targeting a large underserved market with no currently FDA-approved treatment.
A new Israel distribution agreement with Medomie could provide up to $8.2 million in regulatory and commercial milestones, while Verrica will receive 60% of YCANTH’s net selling price. The company continues to pursue additional international partnerships.
A shareholder-provided credit facility offers up to $27.5 million and could extend the cash runway into 2028 without scheduled principal or interest payments until maturity in December 2030, supporting YCANTH expansion and pipeline development.
Despite higher recurring YCANTH revenue, total revenue fell to $5.9 million from $12.7 million a year earlier because the prior-year period included an $8 million milestone payment. Higher R&D and commercial spending, plus a $1.7 million legal-settlement expense, contributed to a $13.2 million GAAP net loss versus net income of $0.2 million a year ago.

Verrica Pharmaceuticals Stock Down 2.7%

NASDAQ VRCA traded down $0.15 during trading on Thursday, reaching $5.36. 84,104 shares of the company’s stock were exchanged, compared to its average volume of 26,664. The company has a 50 day moving average price of $5.81 and a two-hundred day moving average price of $6.06. The stock has a market cap of $92.08 million, a P/E ratio of -5.20 and a beta of 1.49. Verrica Pharmaceuticals has a 1 year low of $3.28 and a 1 year high of $9.82. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.98 and a current ratio of 2.10.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a research note on Wednesday, July 15th. Wall Street Zen cut Verrica Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, July 25th. HC Wainwright initiated coverage on Verrica Pharmaceuticals in a report on Tuesday, May 26th. They set a “buy” rating and a $12.00 price target on the stock. Finally, Zacks Research raised Verrica Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, May 11th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $14.50.

Read Our Latest Stock Report on Verrica Pharmaceuticals

Institutional Investors Weigh In On Verrica Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the business. State Street Corp raised its stake in Verrica Pharmaceuticals by 14.1% during the 4th quarter. State Street Corp now owns 23,481 shares of the company’s stock worth $195,000 after acquiring an additional 2,900 shares in the last quarter. Man Group plc acquired a new position in Verrica Pharmaceuticals in the fourth quarter valued at $94,000. Quadrature Capital Ltd purchased a new position in shares of Verrica Pharmaceuticals during the fourth quarter worth about $99,000. Bridgeway Capital Management LLC purchased a new position in shares of Verrica Pharmaceuticals during the third quarter worth about $52,000. Finally, Beck Mack & Oliver LLC acquired a new stake in shares of Verrica Pharmaceuticals during the fourth quarter worth about $100,000. Institutional investors and hedge funds own 42.45% of the company’s stock.

About Verrica Pharmaceuticals

(Get Free Report)

Verrica Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.